Drawing for DOT

USPTO serial 99770736

DOT

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
GILBERT, REBECCA L
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with DOT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jordan A LaVine

Jordan A LaVine FLASTER GREENBERG PC100 Front Street, Suite 100Conshohocken, PA 19428United States

Goods and services

ClassDescriptionStatusFirst use
042Providing temporary use of on-line non-downloadable cloud computing software using artificial intelligence (AI) for managing, gathering, organizing, and sharing data, information and images in the fields of medical clinical trials and medical research, for the collection of information and data in medical clinical trials and medical research, for evaluating and measuring the performance and results of medical clinical trials and medical research, for medical clinical trial and medical research user and learning management, and for medical clinical trial and medical research operational reporting and analytics; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for managing, gathering, organizing, and sharing data, information and images in the fields of medical clinical trials and medical research, for the collection of information and data in medical clinical trials and medical research, for evaluating and measuring the performance and results of medical clinical trials and medical research, for medical clinical trial and medical research user and learning management, and for medical clinical trial and medical research operational reporting and analytics; Technology consultation and research in the field of data analytics and artificial intelligence technology solutions in the life sciences field; Platform as a service (PAAS) featuring computer software platforms for development and implementation of data analytics and artificial intelligence technology solutions in the life sciences field; Software as a service (SAAS) services featuring software for development and implementation of data analytics and artificial intelligence technology solutions in the life sciences fieldACTIVEFeb 6, 2026

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 22, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 22, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 16, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 27, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 27, 2026DOCKASSIGNED TO EXAMINER—
Aug 26, 2026MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Aug 26, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 17, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 17, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance